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COPD is a common, complex and heterogeneous disease. General objective is to 
identify factors which correction can be translated into improved health care for 
COPD patients. 
The study will take place in Guimarães hospital’s outpatient pulmonology care. COPD 
outpatients over 40 years of age, will be enrolled sequentially in order of appearance 
in the consultation during a one-year period. The most relevant demographic and 
clinical patients’ characteristics will be studied using appropriate tools, and will be 
transformed into variables, which will be used for descriptive and inferential analysis.
The variables degree of severity, medication adherence, beliefs about the disease and 
about the inhaled medications, and the inhalation technique are intended to be related 
to each other, in order to understand the relative weight of each of these variables 
under study as factors of therapeutic success in COPD. 
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BACKGROUND
COPD is the most common chronic 
respiratory disease worldwide with an 
estimated prevalence of 7.6 to 8.9% of 
the adult population1. In Portugal, the 
prevalence may be as high as 14.2% 
in adults over 40 years2. The goals 
of treatment are the improvement of 
symptoms, quality of life, exercise 
tolerance, and prevention of disease 
progression and exacerbations. The 
therapeutic success depends on a 
plurality of factors3, such as appropriate 
treatment, good adherence to medication 
and correct inhalation technique4. 
Adherence to the recommended treat-
ment for COPD and standards of care are 
still unknown in many countries. Many 
studies have shown a general lack of 
knowledge of therapeutic guidelines by 
physicians, and an excessive use of some 
medications, as inhaled corticosteroids, 
in dissonance with the guidelines5.
In COPD, as in many chronic diseases, 
poor adherence to medication are a well-
-known factor of therapeutic failure6, but 
patient’ adherence is not still regularly 
monitored in clinical’ practice7, and it is 
studied only for research purposes. The 
evidence regarding adherence to therapy 
in COPD is not very robust, and seemed 
to be more influenced by patients’ 
beliefs on medicines than by the 
disease severity or other demographic 
factors8. Adherence to treatment and 
its improvement is a critical point in 
patient’s treatment9, but most of the 
investigations referring poor adherence 
patterns in COPD were carried out 
before the use of once or twice daily 
inhaled medication became the rule, and 
many original papers did not describe 
the profiles of patients with regard 
to the degree of dyspnea or airflow 
limitation10. Recently published studies 
reported variability in the prevalence of 
poor adherence, when using different 
methods or instruments, and different 
populations11. Adherence to medication 
remains an open issue, and merits 
further investigation12. 
However important the knowledge 
of adherence to medication, the 
psychometric tools are omitted about 
the reasons for the non-adherence13. 
Sociodemographic variables seems to be 
poor related to adherence behaviors14 
and some authors proposed a study 
protocol in order to better understand 
the factors related to adherence, and 
to intervene positively in patients with 
COPD, exploring motivational and 
cognitive aspects15. The Beliefs about 
Medicines Questionnaire can be useful to 
explore the relationship between beliefs 
and adherence to inhaled medication, in 
COPD patients16,17. 
In the compliant patient, the effectiveness 
of inhaled medication depends on a good 
inhalation technique, a subject not well 
studied in actual pulmonary practice18. 
A large proportion of COPD patients 
use their inhalers incorrectly19,20, and in 
a recent published study assessing the 
use of 3393 inhalation devices, errors 
were observed in over 50% of handlings, 
regardless of the device used21. In 
fact, the inhaler technique has been a 
problem since the launch of the first 
inhaler device, and it is not yet solved22.
In real-life clinical practice, outcomes 
are linked to the inhalation technique, 
to adherence to medication and to the 
ability to found treatable characteristics 
in each patient, based on the best 
medical evidence. Pragmatic studies 
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that reflect real-life clinical practice are 
important in doctors’ clinical judgment, 
and “real-world” research has been 
the focus of an increasing number 
of scientific publications. Its goal is 
to complement classical randomized 
controlled trials (RTCs), representing 
less than 5% of the “real” target patient 
population23. In respiratory medicine, 
RTCs can exclude up to 90% of COPD 
routine care patients. 
OBJECTIVES
The general objective is to understand 
the factors of therapeutic success in 
COPD.  The specific objectives are 1) to 
evaluate the degree of severity of COPD 
outpatients, focused on the symp-
tomatology, number of exacerbations and 
respiratory function; 2) to characterize 
prescribed treatments, determining 
how international guidelines are being 
followed, and identification of major 
deviations; 3) to characterize patient 
adherence to the prescribed inhalation 
therapy, linking it to beliefs about 
inhaled medication, degrees of severity 
and demographic variables, and 4) to 
assess inhalation technique for each of 
the prescribed inhalation devices, in 
order to evaluate their correct use, and its 
relationship with adherence to therapy, 
severity of COPD and demographic 
variables. 
METHODS
The study will take place in the outpatient 
pulmonology care of Guimarães’ hos-
pital, a teaching institution in the North 
of Portugal. Patients will be enrolled 
consecutively after written informed 
consent. The study was approved by 
local ethics committee, the Research 
Ethics Committee of Minho’ University 
and by the Portuguese Data Protection 
Agency (record 5778/2016). Patients 
over 40 years old diagnosed as suffer 
from COPD according to GOLD criteria 
will be included, and the inability to 
understand and respond to simple ques-
tionnaires is the exclusion criterion. A 
survey of demographic and clinical data, 
and the Graffar questionnaire will be 
applied. The Medical Research Council 
Dyspnea Questionnaire (mMRC), the 
COPD Assessment Test (CAT) and the 
referred comorbidities and number of 
acute exacerbations in the last year will 
be used to assess the severity of the 
disease, and its impact on the well-being. 
The evaluation of respiratory function 
will be done according to GOLD criteria. 
We defined exacerbation as a worsening 
of one or more major respiratory symp-
toms, requiring unplanned medical visit 
that led to any treatment or modification 
of previous treatment. 
The Measure of Adherence to Treatment 
Questionnaire (MTA) and the Beliefs 
about Medicines Questionnaire (BMQ) 
will be used respectively to evaluate 
adherence to prescribed therapy and 
the beliefs about the disease and the 
prescribed inhaled therapies24. Finally, 
each patient will be asked to demonstrate 
the use of their prescribed inhalation 
devices, just as he or she does it at 
home. Assessment of errors will be done 
using a checklist for each ID, as defined 
by international recommendations 
for a correct inhalation technique. 
The most relevant demographic and 
clinical characteristics of patients will be 
studied and transformed into variables, 
which will be used for descriptive and 
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inferential analysis. A statistical analysis 
will be performed using the IBM SPSS 
Statistics for Windows software, version 
22.0.
DESIGN
The first task is the study of demographic 
and clinical variables of COPD out- 
-patients and evaluation of morbidity. 
The objective is to access whether some 
clinical or functional characteristics 
can predict an increased risk of acute 
exacerbations of COPD, influencing 
therapeutic options. The second task is 
to evaluate whether symptoms, airflow 
limitation, number of exacerbations, 
Graffar Social Classification and 
adherence to medication, can lead to 
deviations to GOLD 2017 standards of 
treatment. The third task is to measure 
compliance and identify patterns of 
poor adherence to inhaled treatment. 
We intend to assess whether beliefs 
about inhaled medication, the severity 
of COPD, the symptoms, the number 
of acute exacerbations, the type of ID 
or demographic variables, can predict 
patient’s adherence to the prescribed 
inhalation therapy. 
A forth task is to assess if the degree 
of severity of COPD, the degree of 
adherence to treatment, the type of 
ID or demographic factors can predict 
an appropriate inhalation technique. 
Finally, we intend to discuss the relative 
weight and importance of the adherence 
to medication, the compliance with the 
GOLD guidelines and the inhalation 
technique, as factors of therapeutic 
success in COPD, being CAT score, 
mMRC grade and the number of 
exacerbations in the last year the clinical 
outcomes.  
STRENGTHS AND LIMITATIONS 
OF THE STUDY
The study will be conducted in a 
single health care institution, with a 
limited number of patients (up to 350) 
recruited consecutively, so we cannot 
exclude selection bias. Deviations 
from the therapeutic’ standards must 
not be confused with inappropriate 
medication, and, because most patients 
are being treated by pulmonologists, 
fewer deviations from the therapeutic 
standards are expected. Adherence 
to medication is a difficult concept to 
define, but more difficult is to measure 
it, because there is no “best way”. Some 
patients may report higher adherence 
rates than they actually have, but 
self-report questionnaires have high 
specificity for nonadherence. To study 
adherence, MTA was chosen because is 
validated to the Portuguese population. 
However, when compared to the test of 
Adherence to Inhalers, or the Morisky 
Medication Adherence Scale25,26,  it is 
not specific for inhaler devices nor to 
COPD. Assess inhalation technique by 
using checklists with some number of 
steps related to correct use of devices is 
always a subjective evaluation, especially 
the inhalation step. Nonetheless this 
is how, in real-life settings, clinical 
decisions are made in order to prescribe 
IDs. The mMRC and CAT questionnaires 
are validated tools to study dyspnea 
and the global impact of the disease on 
the patient’ well-being, but at present 
there is neither a good definition nor 
an agreed classification of exacerbation, 
and unreported exacerbations also affect 
health status, and contribute to the 
overall severity of the disease. Referred 
COPD acute exacerbations, as defined in 
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this study, could not reflect the overall 
severity of the disease.  As COPD is a 
chronic and incurable disease, the level 
of symptoms and acute exacerbations 
may reflect more the severity of the 
disease than the actual success in the 
treatment of the disease. 
DISCUSSION
Discussion will be focused on the 
characteristics of patients that can lead 
to deviations to therapeutic standards, 
the features of patients that may relate to 
insufficient adherence and that related 
to incorrect inhalation technique. 
The demographic, clinical, and social 
characteristics related to beliefs about 
the disease and the inhaled medication, 
and its relationship with adherence will 
also be discussed. Finally, we intend 
to discuss the relative weight and 
importance of each of these variables 
under study as factors of therapeutic 
success in COPD.
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